Principal Financial Group Inc Intra Cellular Therapies, Inc. Transaction History

Principal Financial Group Inc

$172 Billion
Q4 2024

A detailed history of Principal Financial Group Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 550,963 shares of ITCI stock, worth $70.6 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

550,963

Holding current value

$70.6 Million

% of portfolio

0.03%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 31, 2025	BUY	$71.19 - $91.57 $39.2 Million - $50.5 Million	550,963 New	550,963 $46 Million
Q3 2024 Oct 31, 2024	BUY	$67.99 - $80.84 $1.28 Million - $1.53 Million	18,865 Added 3.26%	597,713 $43.7 Million
Q2 2024 Jul 29, 2024	BUY	$64.76 - $79.84 $3.33 Million - $4.11 Million	51,480 Added 9.76%	578,848 $39.6 Million
Q1 2024 Apr 29, 2024	BUY	$64.37 - $75.65 $4.3 Million - $5.05 Million	66,802 Added 14.5%	527,368 $36.5 Million
Q4 2023 Feb 07, 2024	BUY	$46.37 - $73.65 $2.07 Million - $3.28 Million	44,564 Added 10.71%	460,566 $33 Million
Q3 2023 Nov 02, 2023	SELL	$52.09 - $64.1 $95,428 - $117,431	-1,832 Reduced 0.44%	416,002 $21.7 Million
Q2 2023 Aug 07, 2023	BUY	$54.67 - $66.44 $21.6 Million - $26.2 Million	394,508 Added 1691.28%	417,834 $26.5 Million
Q1 2023 May 09, 2023	SELL	$43.8 - $56.99 $70,211 - $91,354	-1,603 Reduced 6.43%	23,326 $1.26 Million
Q4 2022 Feb 09, 2023	SELL	$44.07 - $54.45 $923,134 - $1.14 Million	-20,947 Reduced 45.66%	24,929 $1.32 Million
Q3 2022 Nov 09, 2022	SELL	$42.7 - $59.99 $6.25 Million - $8.79 Million	-146,465 Reduced 76.15%	45,876 $2.14 Million
Q2 2022 Aug 10, 2022	BUY	$43.0 - $65.64 $5.43 Million - $8.29 Million	126,338 Added 191.41%	192,341 $11 Million
Q1 2022 May 09, 2022	SELL	$38.74 - $62.09 $22,352 - $35,825	-577 Reduced 0.87%	66,003 $4.04 Million
Q4 2021 Feb 09, 2022	BUY	$35.2 - $53.42 $1.24 Million - $1.88 Million	35,208 Added 112.23%	66,580 $3.49 Million
Q3 2021 Nov 09, 2021	BUY	$28.72 - $42.49 $39,978 - $59,146	1,392 Added 4.64%	31,372 $1.17 Million
Q2 2021 Aug 10, 2021	BUY	$29.3 - $44.5 $157,165 - $238,698	5,364 Added 21.79%	29,980 $1.22 Million
Q1 2021 May 10, 2021	BUY	$30.8 - $39.51 $53,099 - $68,115	1,724 Added 7.53%	24,616 $835,000
Q4 2020 Feb 08, 2021	BUY	$23.34 - $32.22 $212,790 - $293,749	9,117 Added 66.19%	22,892 $728,000
Q3 2020 Nov 06, 2020	SELL	$17.61 - $31.86 $3,416 - $6,180	-194 Reduced 1.39%	13,775 $353,000
Q2 2020 Aug 05, 2020	BUY	$14.35 - $26.64 $200,455 - $372,134	13,969 New	13,969 $359,000
Q1 2020 May 12, 2020	SELL	$12.31 - $33.12 $99,144 - $266,748	-8,054 Closed	0 $0
Q4 2019 Feb 05, 2020	BUY	$7.26 - $38.49 $58,472 - $309,998	8,054 New	8,054 $276,000

Others Institutions Holding ITCI

# of Institutions

418

Shares Held

88.6M

Call Options Held

284K

Put Options Held

105K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12.1B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Intra Cellular Therapies, Inc. Transaction History